As much as we would like to see DVLT decouple from Ji's financial dependence right now, and it is happening, Vivasor is still a customer with a license deal.

This deal is just DVLT investing in its own interest. Did we forget about the actual deal between the two? DVLT receives 5% royalty on th sales Vivasor makes via the licensing deal. This is actually bullish af because it signals DVLT is doubling down that Vivasor has actual data worth selling and they're betting it will come back to them down the road. Nate isn't stupid and he's been fighting like hell to get new streams of revenue and grow DVLT. The Vivasor deal stated DVLT could get up to 2.55 billion, everyone was super hyped about this back in the day.

DVLT is also officially worth 50 million more now on paper. It enables them to receive larger loans if needed. Guess who else is worth 50m more? VIvasor. You know who was cash poor? Vivasor. Vivasor now has assets they can trade for a loan to actually pay DVLT the 20m they owe them. This is a massive win win.

The TLDR breakdown:

-License tech to Vivasor (licensee)

-Licensee cant pay dues (cash poor)

-Invest in lincesnsee by adding liquid assets

-Enables licensee to take a loan to pay dues

-Short term dues comes back to licensor (DVLT)

-Long term revenue returns are still open.

-Indicates expected return on investment and license deal.

The original agreement:

https://www.sec.gov/Archives/edgar/data/1682149/000110465925106780/tm2530277d1\_ex10-1.htm?hl=en-US

Vivasor License Agreement

On December 20, 2025, the Company entered into an exclusive license agreement with Vivasor (the “Vivasor License Agreement”), pursuant to which the Company granted to Vivasor a worldwide, exclusive, non-transferable license, with the right to sublicense, to certain patents and other intellectual property rights of the Company – including a suite of patents related to the Company’s data platforms and any products created therefrom within certain targeted industries including medical imaging and scanning – in consideration for a one-time cash payment in the amount of $20.0 million, payable within 120 days following invoicing, a 5% royalty on net sales of products that incorporate or make use of the licensed intellectual property (“Vivasor Product Net Sales”) and multiple one-time sales milestone payments, triggered upon the achievement of certain Vivasor Product Net Sales milestones, in an aggregate amount up to $2.55 billion. During the year ended December 31, 2025, the Company recognized $20.0 million of revenue related to this agreement. As of December 31, 2025, no royalty revenue had been recognized and accounts receivable from Vivasor totaled $20.0 million.

The Vivasor License Agreement expires upon the expiry of the patents underlying the licensed intellectual property, at which point the license shall become perpetual, irrevocable, non-exclusive and royalty-free. The Vivasor License Agreement is subject to earlier termination if, among other things: (i) either party ceases to exist or becomes insolvent, (ii) either party commits a material breach of the Vivasor License Agreement, or (iii) Vivasor fails to make any required payment to the Company that is not cured within 15 days.

Longtime lurker, first time poster. I own about 5k shares. I know we really need revenue to get the price up, so is it safe to assume that revenue is picking up if they have that many job openings? Just curious what your thoughts are

Original post by u/Lordworl, I couldn't crosspost but it was really good writeup and eased my mind a lot personally :)

Event Chain and Financial Flows:

Step 1: The Transaction between the Banks and Vivasor

Under pressure from the Kasowitz lawsuit, the banks (BNY Mellon and St. James) enter into an agreement with Vivasor for a direct purchase of the 75.9 million DVLT shares that Vivasor recently acquired. The price is fixed "above market" (e.g., $1.50–$2.00 per share).

Outcome: The banks spend approximately $150 million but secure a physical block of shares to close their legal "gaps."

Step 2: Capitalizing Vivasor

Vivasor receives the cash ($150 million) from the banks into its accounts. It is no longer just a company with patents, but a financially stable biotech player with a massive cash reserve.

Step 3: Cleaning Up Datavault AI’s (DVLT) Balance Sheet

Vivasor uses a portion of the funds received from the banks (e.g., $50–$70 million) to:

Repurchase its own shares that were previously transferred to DVLT in exchange for an equity stake.

Fully settle the outstanding $20 million debt for software licenses.

Outcome: DVLT sees actual cash on its balance sheet, and the questionable accounts receivable disappear.

Step 4: Settlement of the Kasowitz Lawsuit

The banks transfer the shares purchased from Vivasor to Scilex’s accounts (as restoration of collateral or compensation for the "missing" 96 million shares).

Outcome: Scilex (Henry Ji) recovers its assets in full. All claims are satisfied, and Marc Kasowitz withdraws the lawsuit under a Settlement Agreement.

Step 5: Final Status of the Parties

The Banks: Resolved legal risks and claims regarding the 96 million shares.

Vivasor: Retains a net balance of approximately $80–$100 million for drug development.

DVLT: Holds $50+ million in cash, making its financial reporting highly attractive.

Henry Ji: Maintained control over all entities, capitalized them, and ended the litigation war with major U.S. banks.

Legal and Financial Reality:

This structure is known as a "Tripartite Settlement Agreement." It is entirely legal, as companies have the right to engage in private equity transactions (Private Placements) at negotiated prices. In official SEC filings, this would be reported as a "Subsequent Event: Settlement of Litigation and Strategic Investment."

I am not invested here but everywhere I go I see positive news about this company from massive revenue to contracts to fund investors yet the stock is like a rock not moving at all can someone help me understand?

This post contains content not supported on old Reddit. Click here to view the full post